We live in a culture of acceleration. Everything moves faster now—our internet, our shipping, our news cycles. So it's natural that we've brought this mindset into medicine, where we celebrate breakthroughs that work quickly and dismiss anything that takes time. But I'd argue we're making a mistake. The unpopular take is that restraint, not speed, may be the smarter strategy here.
Consider the current landscape of medical advancement. Recent headlines trumpet drugs that double survival times and treatments offering one-and-done prevention. These are genuinely exciting developments. Nobody wants to wait for better health outcomes. But in our rush to celebrate speed, we're overlooking something crucial: the difference between fast adoption and wise adoption.
The problem with our speed obsession shows up in real patient experiences. When conditions take years to diagnose properly, it's often because we're moving too quickly through the possibilities. Hidradenitis suppurativa, for instance, is frequently misdiagnosed because doctors move fast and land on the wrong answer. The solution isn't to move even faster. It's to slow down enough to listen, observe, and reconsider.
This principle applies across medicine. Yes, rapid drug development can save lives. But rushing a treatment to market without adequate post-launch monitoring has historically created new problems. Speed and safety aren't always aligned. Sometimes the restraint to say "let's gather more long-term data" is the responsible choice, even if it feels counterintuitive in our acceleration-obsessed moment.
I'm not arguing against medical innovation. Absolutely pursue breakthrough treatments for pancreatic cancer, heart disease, hair loss, and everything else that diminishes human wellbeing. But pursue them with the understanding that implementation speed and scientific robustness are different questions. A treatment can be scientifically sound but still warrant careful, measured rollout.
There's also the matter of equity. When we prioritize speed, we often inadvertently prioritize access for those who can move fastest through the system: the wealthy, the well-connected, those in major medical centers. A more restrained approach, focused on careful implementation and equitable distribution, might serve more people better in the long run.
Furthermore, medical systems need time to adapt. When new treatments arrive faster than practitioners can be trained to use them properly, we create a mismatch between innovation and competence. Healthcare workers deserve the space to learn thoroughly, not just quickly.
The cultural message matters too. Our speed obsession tells patients that faster treatment equals better treatment, but that's not always true. Sometimes the most loving thing a doctor can do is recommend careful observation over immediate intervention. Sometimes the wisest patient is the one who asks more questions before proceeding.
None of this means we should slow down scientific research or regulatory approval for genuinely life-saving treatments. Rather, it means we should be thoughtful about distinguishing between the speed of innovation and the speed of implementation. These aren't the same thing.
The next time you see a headline about a medical breakthrough, ask yourself: Is this celebrating speed for speed's sake, or speed paired with appropriate caution? Is this a genuine advance we should accelerate, or something we should implement with measured wisdom?
Our culture needs permission to move deliberately in medicine. We need doctors who feel comfortable saying "let's take time to get this right." We need patients who accept that sometimes the most modern choice is the most patient one.
Speed isn't always medicine's best friend. Restraint might be.